TABLE 1

Baseline characteristics by genotypic resistance profile

CharacteristicValue for groupaP valueb
LAM/ETV-R (n = 45)LAM/ADV-R (n = 28)LAM/ETV/ADV-R (n = 20)
Age (yr)c56 (32–71)50.5 (23–68)54 (29–67)0.499
Male gender31 (68.9)22 (78.6)14 (70.0)0.652
Serum HBV DNA (log10 IU/ml)c3.66 (0.87–7.37)2.95 (1.88–6.71)2.60 (2.02–8.23)0.116
Serum ALT (IU/liter)c30 (9–275)27.5 (11–843)26.5 (14–57)0.636
Serum creatinine (mg/dl)c0.86 (0.53–1.26)0.88 (0.53–1.31)0.86 (0.54–1.14)0.869
HBeAg positive31 (68.9)18 (64.3)14 (70.0)0.893
Liver cirrhosisd16 (35.6)8 (28.6)4 (20.0)0.469
Lines of prior antiviral treatment2 (1–5)3 (2–5)5 (3–5)<0.001
Duration of previous treatment (mo)c28.2 (2.7–78.7)17.5 (2.7–85.7)17.5 (1.4–40.2)0.028
Time point of rescue therapy
    Virologic breakthrough21 (46.7)11 (39.3)5 (25.0)0.257
    Biochemical breakthrough17 (37.8)6 (21.4)6 (30.0)0.339
  • a Unless otherwise indicated, data are number of patients, with percentages in parentheses. LAM, lamivudine; ETV, entecavir; ADV, adefovir; HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.

  • b The Kruskal-Wallis test and χ2 test (or Fisher's exact test) were used to analyze the differences among the groups.

  • c Data are medians, with ranges in parentheses.

  • d Liver cirrhosis was diagnosed when the platelet count was below 100,000/mm3 and associated splenomegaly or esophageal-gastric varices were detected.